Displaying drugs 5626 - 5650 of 6998 in total
(3-Chloro-4-Propoxy-Phenyl)-Acetic Acid
Experimental
(Carboxyhydroxyamino)Ethanoic Acid
Experimental
Aspartic Acid-4-Carboxymethyl Ester
Experimental
Thieno[2,3-B]Pyridine-2-Carboxamidine
Experimental
1-CHLORO-6-(4-HYDROXYPHENYL)-2-NAPHTHOL
Experimental
5-(2-CHLORO-4-NITROPHENYL)-2-FUROIC ACID
Experimental
9-(N-methyl-L-isoleucine)-cyclosporin A
9-(N-methyl-L-isoleucine)-cyclosporin A (NIM811) has been used in trials studying the treatment of Chronic Hepatitis C Genotype-1 Relapse.
Investigational
Matched Description: … N-methyl-L-isoleucine)-cyclosporin A (NIM811) has been used in trials studying the treatment of Chronic Hepatitis C …
Recombinant human type VII collagen
Investigational
Olvimulogene nanivacirepvec
Olvimulogene nanivacirepvec is under investigation in clinical trial NCT01443260 (A Study of GL-ONC1, an Oncolytic Vaccinia Virus, in Patients With Advanced Peritoneal Carcinomatosis).
Investigational
Belzupacap Sarotalocan
Investigational
Socazolimab
Socazolimab is under investigation in clinical trial NCT04878016 (A Study of Carboplatin Plus Etoposide With or Without ZKAB001 (Anti-pd-l1 Antibody) in Patients With ES-SCLC).
Investigational
Apamistamab iodine I-131
Investigational
Vodobatinib
Investigational
3,4-Dihydro-2h-Pyrrolium-5-Carboxylate
Experimental
1-(4-Amidinophenyl)-3-(4-Chlorophenyl)Urea
Experimental
4,6-O-(1-Carboxyethylidene)-Beta-D-Glucose
Experimental
D-leucyl-N-(3-chlorobenzyl)-L-prolinamide
Experimental
3',5'-DIFLUOROBIPHENYL-4-CARBOXYLIC ACID
Experimental
1-PHENYL-1H-PYRAZOLE-4-CARBOXYLIC ACID
Experimental
Anti-SARS-CoV-2 equine immunoglobulin fragments
Anti-SARS-CoV-2 equine immunoglobulin fragments, also known as INOSARS, is a polyvalent passive immunization being tested in the clinical trial NCT04514302 (Safety and Efficacy of Anti-SARS-CoV-2 Equine Antibody Fragments (INOSARS) for Hospitalized Patients With COVID-19). INOSARS is composed of F(ab’)2 fragments extracted from hyperimmune equine serum.
Investigational
Sanglifehrin A
Experimental
Matched Iupac: … (3S,6S,9R,10R,11S,12S,13E,15E,18S,21S)-18-[(2E,4E,8S,9S)-10-[(2S,3R,4S,5S,6R,9S,11S)-9-ethyl-4-hydroxy …
Andecaliximab
Andecaliximab is a monoclonal antibody directed against matrix metallopeptidase 9 (MMP9). Andecaliximab is under investigation in clinical trial NCT03631836 (Phase I Study of Monoclonal Antibondy (GS) 5745, an Matix Metalloproteinase 9 (MMP9) Mab Inhibitor, in Combination With Bevacizumab in Patients With Recurrent Glioblastoma).
Investigational
Displaying drugs 5626 - 5650 of 6998 in total